Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer:a post hoc analysis of the AXEPT study  

作　　者：Satoru Iwasa Zi-Xian Wang Kei Muro Satoshi Morita Young Suk Park Dongsheng Zhang Yasuhide Yamada Junichi Sakamoto TaeWon Kim 

机构地区：[1]Department of Gastrointestinal Medical Oncology,National Cancer Center Hospital,Tokyo,Japan [2]Department of Medical Oncology,Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,P.R.China [3]Department of Clinical Oncology,Aichi Cancer Center Hospital,Nagoya,Japan [4]Department of Biomedical Statistics and Bioinformatics,Graduate School of Medicine,Kyoto University,Kyoto,Japan [5]Division of Hematology-Oncology,Department of Medicine,Samsung Medical Center,Sungkyunkwan University School of Medicine,Seoul,Korea [6]Comprehensive Cancer Center,National Center for Global Health and Medicine,Tokyo,Japan [7]Department of Medical Oncology,Hamamatsu University School of Medicine,Shizuoka,Japan [8]Tokai Central Hospital,Kakamigahara,Japan [9]Department of Oncology,Asan Medical Center,University of Ulsan,College of Medicine,Seoul,Korea

出　　处：《Cancer Communications》2023年第4期519-522,共4页癌症通讯（英文）

摘　　要：Dear Editor,Recently,the phase III Asian XELIRI(capecitabine plus irinotecan)ProjecT(AXEPT)study demonstrated the non-inferiority of modified capecitabine plus irinotecan(mXELIRI)±bevacizumab(Bev)to fluorouracil plus leucovorin with irinotecan(FOLFIRI)±Bev in terms of overall survival(OS)as a second-line treatment for patients with metastatic colorectal cancer[1,2].In the past decade,oral prodrugs of fluorouracil-containing regimens have shown similar efficacies to intravenous fluorouracilcontaining regimens.

关 键 词：FOLFIRI colorectal METASTATIC 

分 类 号：R735.34[医药卫生—肿瘤]